Can Long-Term tucatinib use remain safe for HER2-Positive cancers?
NCT ID NCT07768358
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and tolerability, tracking serious side effects and any reasons for stopping treatment. Participants will keep taking tucatinib twice daily while researchers collect additional safety data to better understand its profile over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tucatinib (TUKYSA), an oral targeted cancer drug taken twice daily
- What this could lead to
- If successful, this study could confirm the long-term safety of tucatinib for people with HER2-positive cancers, supporting its continued use as a maintenance therapy.
- What could go wrong
- This is an open-label continuation study without a comparison group, so it cannot prove effectiveness. Safety monitoring may reveal new side effects with longer use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat gynecological tumors?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?